RBC Capital Sticks to Its Buy Rating for Eagle Pharmaceuticals Inc (EGRX)

By Ryan Adsit

In a report issued on August 8, Randall Stanicky from RBC Capital maintained a Buy rating on Eagle Pharmaceuticals Inc (EGRXResearch Report), with a price target of $66. The company’s shares closed on Friday at $56.99.

According to TipRanks.com, Stanicky ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -19.2% and a 22.2% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Osmotica Pharmaceuticals Plc, and Amneal Pharmaceuticals Inc.

The the analyst consensus on Eagle Pharmaceuticals Inc is currently a Hold rating.

See today’s analyst top recommended stocks >>

Based on Eagle Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $6.73 million. In comparison, last year the company had a net profit of $2.66 million.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.